Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy

Journal of Urology

Volumn 155, Issue 3, 1996, Pages 982-985

  Moul, Judd W ^a   Maygarden, Susan J ^b   Ware, Joy L ^b   Mohler, James L ^b   Maher, Paul D ^b   Schenkman, Noah S ^b   Ho, Chi K ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NONE

Author keywords

cathespin; immunohistochemistry; prostatectomy; prostatic neoplasms

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

EID: 0030033246     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66362-6     Document Type: Article

References (33)

1. Boring, C. C., Squires, T. S., Tong, T. and Montgomery, S.: Cancer statistics, 1994. CA, 44: 7, 1994.
2. Carter, H. B. and Coffey, D. S.: The prostate: an increasing medical problem. Prostate, 16: 39, 1990.
3. Lu-Yao, G. L., McLerran, D., Wasson, J. and Wennberg, J. E.: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. J.A.M.A., 269: 2633, 1993.
4. Wasson, J. H., Cushman, C. C., Bruskewitz, R. C., Littenberg, B., Mulley, A. G., Jr. and Wennberg, J. E.: A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch. Fam. Med., 2: 487, 1993.
5. Ware, J. L.: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev., 12: 287, 1993.
6. Stearns, M. E., Wang, M. and Stearns, M.: Proteases and invasion by metastatic tumor cells: clinical implications for prostate cancer. Int. J. Oncol., 4: 1013, 1994.
7. Maygarden, S. J., Strom, S. and Ware, J. L.: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch. Path. Lab. Med., 116: 269, 1992.
8. Ibrahim, G. K., Kerns, B. M., MacDonald, J. A., Ibrahim, S. N., Kinney, R. B., Humphry, P. A. and Robertson, C. N.: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J. Urol., 149: 170, 1993.
9. Visakorpi, T., Kallioniemi, O. P., Koivula, T., Harvey, J. and Isola, J.: Expression of epidermal growth factor receptor and ERBB-2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod. Path., 5: 643, 1992.
10. Myers, R. B., Kudlow, J. E. and Grizzle, W. E.: Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod. Path., 6: 733, 1993.
11. Montone, K. T. and Tomaszewski, J. E.: In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J. Clin. Lab. Anal., 7: 188, 1993.
12. Mellon, K., Thompson, S., Charlton, R. G., Marsh, C., Robinson, M., Lane, D. P., Harris, A. L., Horne, C. H. W. and Neal, D. E.: p53, c-erbB-2 and the epidermal growth factor receptor in benign and malignant prostate. J. Urol., 147: 496, 1992.
13. Maygarden, S. J., Novotny, D. B., Moul, J. W., Bae, V. L. and Ware, J. L.: Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod. Path., 7: 930, 1994.
14. Turkeri, L. N., Sakr, W. A., Wykes, S. M., Grignon, D. J., Pontes, J. E. and Macoska, J. A.: Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate, 25: 199, 1994.
15. Fox, S. B., Persad, R. A., Collins, C. C., Royds, J. and Silcocks, P. B.: EGFR, C-erbB-2, p53 and c-myc expression in stage A1 prostate adenocarcinoma: prognostic determinants? J. Urol., part 2, 149: 331A, abstract 475, 1993.
16. Barrett, A. J.: Cathepsin D and other carboxyl proteinase. In: Proteinase in Mammalian Cells and Tissues. Edited by A. J. Barrett. Amsterdam: Elsevier/North Holland, p. 209, 1977.
17. Thorpe, S. M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I. J., Khalaf, S., Paolucci, F., Pau, B., Rasmussen, B. B. and Rose, C.: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res., 49: 6008, 1989.
18. Spyratos, F., Maudelonde, T., Brouillet, J. P., Brunet, M., Defrenne, A., Andrieu, C., Hacene, K., Desplaces, A., Rouesse, J. and Rochefort, H.: Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet, 2: 1115, 1989.
19. Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M. and McGuire, W. L.: Cathepsin D and prognosis in breast cancer. New Engl. J. Med., 322: 297, 1990.
20. Henry, J. A., McCarthy, A. L., Angus, B., Westley, B. R., May, F. E., Nicholson, S., Cairns, J., Harris, A. L. and Horne, C. H.: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer, 65: 265, 1990.
21. Makar, R., Mason, A., Kittelson, J. M., Bowden, G, T., Cress, A. E. and Nagel, R. B.: Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod. Path., 7: 747, 1994.
22. Chambon, M., Rebillard, X., Rochefort, H., Brouillet, J. P., Baldet, P., Guiter, J. and Maudelonde, T.: Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors. Prostate, 24: 320, 1994.
23. Kuczyk, M. A., Serth, J., Denil, J., Höfner, K., Allhoff, E. P. and Jonas, U.: Cathepsin D expression and the possible role of lysosomal proteases as a prognostic factor in prostate cancer. J. Urol., part 2, 151: 286A, abstract 234, 1994.
24. Gleason, D. F.: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 9, pp. 171-198, 1977.
25. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74: 104, 1994.
26. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
27. Budwit-Novotny, D. A., McCarty, K. S., Cox, E. B., Soper, J. T., Mutch, D. G., Creasman, W. T., Flowers, J. L. and McCarty, K. S., Jr.: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res., 46: 5419, 1986.
28. Mellon, K., Wright, C., Kelly, P., Horne, C. H. W. and Neal, D. E.: Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J. Urol., part 2, 153: 919, 1995.
29. χ and the epidermal growth factor receptor in human prostate tissues. J. Urol., 152: 2120, 1994.
30. Fong, C. J., Sherwood, E. R., Mendelsohn, J., Lee, C. and Kozlowski, J. M.: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res., 52: 5887, 1992.
31. Veltri, R. W., Partin, A. W., Epstein, J. L, Criley, S. R., Wright, G. L., Jr., Marley, G. M., Miller, M. C., Singer, D. P., Patton, K. P. and Coffey, D. S.: Prognostic value of multivariate analysis of biomarkers for prostate cancer progression and staging following radical prostatectomy. Proc. Amer. Ass. Cancer Res., 35: 203, abstract 1211, 1994.
32. Yang, Y., Chisholm, G. D. and Habib, F. K.: The distribution of PSA, cathepsin-D, and pS2 in BPH and cancer of the prostate. Prostate, 21: 201, 1992.
33. Moul, J. W., Gaddipati, J. and Srivastava, S.: Molecular biology of prostate cancer: oncogenes and tumor suppressor genes. In: Prostate Cancer. Edited by N. A. Dawson and J. J. Vogelzang. New York: Wiley-Liss, Inc., pp. 19-46, 1994.